Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines

Avi Cherla; Anita K Wagner; Olivier J Wouters; Steven Woloshin; Courtney Davis; Elias Mossialos; Huseyin Naci

doi:10.1001/jama.2025.13917

Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines

JAMA. 2025 Oct 28;334(16):1480-1482. doi: 10.1001/jama.2025.13917.

Authors

Avi Cherla^{1

2}, Anita K Wagner^{2

3}, Olivier J Wouters⁴, Steven Woloshin^{3

5}, Courtney Davis^{3

6}, Elias Mossialos¹, Huseyin Naci^{1

2

3}

Affiliations

¹ Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.
² Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
³ Lisa Schwartz Foundation for Truth in Medicine, Norwich, Vermont.
⁴ Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island.
⁵ Center for Medicine in the Media, Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
⁶ Department of Global Health and Social Medicine, King's College London, London, United Kingdom.

No abstract available

Plain language summary

This study assesses the reporting by journal publications and National Comprehensive Cancer Network (NCCN) guidelines of clinical uncertainties identified by the US Food and Drug Administration’s (FDA) Benefit-Risk Framework pertaining to cancer drugs approved in 2019-2022.